Corbus Pharmaceuticals Holdings, Inc. (CRBP)

0.1447 +0.0047 (+3.36%) At close: 04:00PM EST

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 41

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yuval Cohen Ph.D.	CEO & Director	846.92k	N/A	1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA	Chief Financial Officer	542k	N/A	1958
Mr. Craig Stuart Millian M.B.A.	Chief Operating Officer	542k	N/A	1969
Dr. Rachael Brake Ph.D.	Chief Scientific Officer	N/A	N/A	1972
Ted Jenkins	Sr. Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Lindsey Smith	Head of Corp. Communications & Patient Advocacy	N/A	N/A	N/A
Ms. Christina Bertsch	Head of HR	N/A	N/A	N/A
Scott Constantine	Sr. Director & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 28 January 2023 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.